317450.KO MYUNG IN PHARMA CO LTD
- Market cap
- KRW 611B
- P/E
- 6.7x
- P/B
- 0.72x
- ROE
- 11.5%
- Dividend yield
- 1.83%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 317450.KO undervalued?
Graham number317450.KO trades 53.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MYUNG IN PHARMA CO LTD fundamental analysis
No fundamental analysis for MYUNG IN PHARMA CO LTD yet.
MYUNG IN PHARMA CO LTD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MYUNG IN PHARMA CO LTD
Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides AP…
Full company profileMYUNG IN PHARMA CO LTD financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MYUNG IN PHARMA CO LTD annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 209B | - | 287B | 296B |
| Gross Profit | - | - | 174B | 186B |
| Operating Income | - | - | 92.5B | 105B |
| EBITDA | - | - | 113B | 134B |
| Net Income | - | 57.4B | 81.4B | 94.1B |
| EPS | - | - | 5,578 | 6,446 |
| Balance Sheet | ||||
| Total Assets | - | - | 842B | 868B |
| Total Liabilities | 53.7B | - | 47.3B | 52.1B |
| Shareholders' Equity | 376B | - | 794B | 816B |
| Cash & Short-term Investments | 53.0B | - | 31.8B | 26.7B |
| Cash Flow | ||||
| Operating Cash Flow | - | 61.0B | 81.6B | 79.6B |
| Capital Expenditure | 0.00 | 0.00 | 34.8B | 55.0B |
| Free Cash Flow | - | 57.6B | 46.7B | 24.6B |
| Ratios | ||||
| ROE | - | - | 10.3% | 11.5% |
| ROA | - | - | 9.7% | 10.8% |
| Net Profit Margin | - | - | 28.3% | 31.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MYUNG IN PHARMA CO LTD dividends
- Dividend yield
- 1.83%
- Forward dividend
- 2,000.00 KRW
- Payout ratio
- 13.8%
- Ex-dividend date
- Aug 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 11.2B | 767 | 13.8% |
| 2024 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns MYUNG IN PHARMA CO LTD
- Insiders 76.31%
- Institutions 0.27%
- Public & others 23.42%
- Shares outstanding 14.6M
- Free float 2.51M
MYUNG IN PHARMA CO LTD company profile
- Company name
- MYUNG IN PHARMA CO LTD
- Ticker
- 317450.KO
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Fiscal year end
- December
- Address
- 361-12, Noha-gil, Hwaseong-si, South Korea
- Phone
- 82 2 587 9060
- Website
- myunginph.co.kr
About MYUNG IN PHARMA CO LTD
Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate, haloperidol, paroxetine hcl, pimozide, quetiapine fumarate, rasagiline mesylate, risperidone, sumatriptan succinate, trazodone hci, triazolam, levetiracetam, carbamazepine, benserazide hydrochloride, escitalopram oxalate, vortioxetine hbr, brivaracetam, edoxban tosylate, opicapone, brexpiprazole, guanfacine hydrochloride, lacosamide, lurasidone hydrochloride. Myung In Pharmaceutical LTD. was founded in 1985 and is based in Hwaseong-si, South Korea.
MYUNG IN PHARMA CO LTD management
10- Mr. Hang-Myung LeeChairman, CEO & President · born 1949
- Mr. Dongcheol LeePresident, Chief Administrative Officer & Director · born 1959
- Mr. BongKwon ChaPresident & Chief Sales Officer · born 1963
- Mr. Haesuk OhMD, Head of Finance Division Director · born 1967
- Mr. Hohyeong ChoiMD & Quality Control Manage of Plant 1 · born 1970
- Ms. Hyesook NaMD & Quality Control Manager of Plant 2 · born 1967
- Mr. Hyunkyu KimMD & Director of the Synthetic Research Lab of Plant 2 · born 1969
- Mr. JaeHyung MoMD & Director of Sales Management · born 1969
- Mr. JungWook LeeMD and Head of Research & Development Division · born 1974
- Mr. SeonBok YoonMD & Director of General Hospital · born 1966